Nektar Therapeutics’ (NKTR) New Drug Application for Oxycodegol is scheduled to be reviewed by the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on January 14, 2020.Oxycodegol, also known as NKTR-181, is proposed for the management of chronic low back pain in adult patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.NKTR closed Monday’s (Dec.30, 2019) trading at $20.77, down 3.71%.